FDA regulatory milestone announcements (510(k) clearance decisions, IDE approvals for pivotal trials)
Clinical trial data readouts showing efficacy/safety for dermatology or oncology indications
Strategic partnership announcements with established medical device distributors or pharmaceutical companies
Intellectual property developments (patent grants, litigation outcomes affecting NPS technology exclusivity)
moderate - As a pre-revenue company, near-term stock performance is insulated from economic cycles and driven by binary clinical/regulatory events. Post-commercialization, dermatology/aesthetic procedures are elective and discretionary, making demand moderately sensitive to consumer confidence and disposable income. Medical aesthetics spending correlates with wealth effects and employment stability, with 20-30% demand variability during recessions. Oncology applications would be less cyclical due to medical necessity.
High sensitivity through multiple channels: (1) Valuation compression as rising rates increase discount rates applied to distant future cash flows, disproportionately impacting pre-revenue growth stocks trading on 2028+ earnings potential. (2) Financing costs for future debt raises, though current 10.02x current ratio and 0.09 debt/equity suggest minimal near-term debt dependency. (3) Competitive cost of capital for target customers (dermatology practices) financing equipment purchases, potentially slowing adoption. 100bp rate increase historically compresses pre-revenue medtech valuations by 15-25%.
FDA regulatory rejection or delayed approval pathway requiring additional clinical trials, extending time-to-market by 18-36 months and exhausting cash reserves before revenue generation
Reimbursement uncertainty as payers may classify NPS procedures as cosmetic/experimental, limiting adoption to cash-pay markets and capping addressable market at 30-40% of initial projections
Technology obsolescence risk if competing energy modalities (plasma, focused ultrasound) demonstrate superior outcomes or safety profiles before Pulse achieves market penetration
growth/speculative - Attracts biotech-focused growth investors and venture capital crossover funds seeking asymmetric returns from successful FDA approval and commercialization. High-risk, high-reward profile with binary outcomes. Recent 74% three-month return and 51% six-month return indicate momentum-driven trading and speculation around regulatory catalysts. Not suitable for value or income investors given negative cash flows, no dividends, and unproven business model. Institutional ownership likely concentrated among healthcare specialist funds with high risk tolerance.
Trend
+55.1% vs SMA 50 · +85.8% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $150000 $131151–$168800 | — | -$1.02 | — | ±16% | Low1 |
FY2026(current) | $3.1M $2.7M–$3.6M | ▲ +2000.0% | -$1.10 | — | ±16% | Low2 |
FY2027 | $12.5M $11.0M–$14.0M | ▲ +296.8% | -$1.15 | — | ±16% | Low2 |
INSTITUTIONAL OWNERSHIP
PLSE News
About
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
PLSE◀ | $24.55 | -9.41% | $1.7B | — | — | -2079457.1% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.98% | — | 50.3 | +398824.8% | -300567.2% | 1500 |